Please check your internet connection and try again.
```markdown
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis and reduction in associated heartburn
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. In some patients, 20 mg orally once daily may be sufficient.
* **Symptomatic GERD:** 40 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Start with 40 mg orally or intravenously twice daily. Doses may be increased to 240 mg daily and administered every 8 hours as needed.
## Pediatric Dosing
Dosing in pediatric patients is highly variable and often relies on weight-based calculations and local protocols.
* **Children 5 to 16 years:**
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Symptomatic GERD:** 20 mg orally once daily for up to 4 weeks.
* **Use in younger children is generally not recommended due to limited data.**
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, flatulence.
* **Serious:** Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia (can be severe, may lead to hypocalcemia, hypokalemia, tetany, seizures, cardiac arrhythmias), vitamin B12 deficiency, systemic lupus erythematosus.
## Key Drug Interactions
* **Rilpivirine:** Decreased rilpivirine plasma concentrations; concomitant use is contraindicated.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Drugs Dependent on Gastric pH for Absorption:** PPIs can alter gastric pH, affecting the absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir).
* **Clopidogrel:** May decrease the antiplatelet effect of clopidogrel; consider alternative or avoid if possible.
* **Sucralfate:** May decrease absorption of pantoprazole; administer pantoprazole at least 30 minutes before sucralfate.
## Monitoring
* Monitor for signs and symptoms of Clostridium difficile infection.
* Consider monitoring serum magnesium levels in patients on long-term therapy, especially if taking concomitant medications like digoxin or diuretics.
* Assess for bone fracture risk in patients with risk factors for osteoporosis.
* Monitor for signs and symptoms of vitamin B12 deficiency with prolonged use.
## Clinical Pearls
* Pantoprazole is available in oral (delayed-release tablets, granules) and intravenous formulations.
* Oral pantoprazole should be taken at least 1 hour before a meal.
* IV pantoprazole should be administered as an infusion over 15 minutes or as a slow IV injection over 2 minutes.
* Long-term use of PPIs is associated with increased risks of fractures, C. difficile infection, and hypomagnesemia. Consider the shortest duration of therapy needed to treat the condition.
* For patients unable to swallow intact tablets, the delayed-release granules can be mixed with applesauce or apple juice.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your institution's protocols before making any treatment decisions.
```
